Prager Franz, Michels Stephan, Geitzenauer Wolfgang, Schmidt-Erfurth Ursula
Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Acta Ophthalmol Scand. 2007 Dec;85(8):904-6. doi: 10.1111/j.1600-0420.2007.00927.x. Epub 2007 Apr 13.
A case of choroidal neovascularization (CNV) secondary to Sorsby fundus dystrophy (SFD) treated with systemic bevacizumab (Avastin).
A 41-year-old woman presented with CNV secondary to SFD in her better eye. The patient received three initial infusions of bevacizumab at a dose of 5 mg/kg at 2 week intervals and one additional infusion because of CNV recurrence at the 7 month follow-up.
At 16 month follow-up, visual acuity had improved from 20/50 at baseline to 20/25; optical coherence tomography and fluorescein angiography showed no evidence of CNV activity.
Systemic bevacizumab seems to be a promising treatment option for CNV secondary to SFD.
报告1例采用全身注射贝伐单抗（阿瓦斯汀）治疗的索斯比眼底营养不良（SFD）继发脉络膜新生血管（CNV）病例。
一名41岁女性较好眼患有SFD继发CNV。患者最初每2周接受3次剂量为5mg/kg的贝伐单抗注射，在7个月随访时因CNV复发又接受了1次注射。
在16个月的随访中，视力从基线时的20/50提高到了20/25；光学相干断层扫描和荧光素血管造影显示无CNV活动迹象。
全身注射贝伐单抗似乎是治疗SFD继发CNV的一种有前景的治疗选择。
Zotero 插件